Pangea Bio
Pangea Bio develops small-molecule therapeutics for neurological and neuropsychiatric disorders by mining nature’s chemical space and human ethnobotanical evidence. The company combines AI-driven drug discovery with natural-product chemistry and preclinical pharmacology to identify and optimize TrkB-activating and other CNS-targeted molecules. It operates as a biotechnology research and drug-development organization (B2B) that offers research services and SaaS tools for pharmaceutical partners. Pangea’s scalable CNS pipeline is centered on nature-inspired compounds and includes lead asset OT-003, which is scheduled to enter Phase 1 studies in 2025. The approach targets large unmet needs in CNS disorders by integrating AI, ethnobotany, and traditional safety evidence to accelerate candidate selection.
Pangea Bio
Pangea Bio develops small-molecule therapeutics for neurological and neuropsychiatric disorders by mining nature’s chemical space and human ethnobotanical evidence. The company combines AI-driven drug discovery with natural-product chemistry and preclinical pharmacology to identify and optimize TrkB-activating and other CNS-targeted molecules. It operates as a biotechnology research and drug-development organization (B2B) that offers research services and SaaS tools for pharmaceutical partners. Pangea’s scalable CNS pipeline is centered on nature-inspired compounds and includes lead asset OT-003, which is scheduled to enter Phase 1 studies in 2025. The approach targets large unmet needs in CNS disorders by integrating AI, ethnobotany, and traditional safety evidence to accelerate candidate selection.
TL;DR
What they do: AI-driven biotech discovering nature-inspired CNS therapeutics
Headquarters: Sevenoaks, Kent, United Kingdom
Founded: 2021
Lead asset: OT-003 entering Phase 1 in 2025
Reported funding: Reported total ~$15M; investors include Empath Ventures, Eretz.bio, Globivest, Kadmos Capital, No Label Ventures, Seaside Ventures
Company Overview
Problem Domain
Central nervous system and neuropsychiatric therapeutic development
Founded
2021
Industry
Biotechnology
Tech Stack
Funding Track Record
Convertible-note entry recorded on company profile
Series A recorded on company profile
Investor Signal
“Empath Ventures, Eretz.bio, Globivest, Kadmos Capital, No Label Ventures, Seaside Ventures”